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OBJECTIVES We sought to determine the survival experiences of patients bridged to heart transplantation
with either intravenous (IV) inotropes or an implantable left ventricular assist device
(LVAD).
BACKGROUND Because of the operative risks of LVAD implantation and the reported lower mortality
associated with inotropic therapy, bridging to heart transplantation with inotropes is thought
to be the preferred treatment option.
METHODS Between April 1, 1996, and May 10, 2001, a total of 104 patients were bridged to heart
transplantation with either IV inotropes (n  38) or an implantable LVAD (n  66;
HeartMate). Survival was compared (Kaplan-Meier method) for three periods: survival to
transplantation, post-transplantation survival and overall survival (i.e., survival from the onset
of bridging to follow-up).
RESULTS Survival to transplantation was 81 5% at three months for the LVAD group and 64 11%
for the inotrope group (p  NS). Post-transplantation survival was 95  4% at three years
for the LVAD group (two deaths) and 65  10% at three years for the inotrope group (nine
deaths; p  0.007). Overall survival was 77  6% at three years for the LVAD group and
44  9% at three years for the inotrope group (p  0.01).
CONCLUSIONS Overall survival for patients who were bridged to heart transplantation with an implantable
LVAD was superior to that of patients who were bridged with inotropes. Bridging to
transplantation with an implantable LVAD improves utilization of donor hearts. (J Am
Coll Cardiol 2002;39:1247–54) © 2002 by the American College of Cardiology Foundation
Both intravenous (IV) inotropes and a left ventricular assist
device (LVAD) can be used to bridge patients successfully
to heart transplantation when standard oral medications are
inadequate. In standard contemporary practice, IV ino-
tropes are initially preferred because of the substantial risk of
early mortality and morbidity associated with LVAD use
(1–3). In contrast, inotropic therapy is associated with low
morbidity and mortality (4).
However, consideration of the different mortality risks
associated with inotropic and LVAD therapy during the
bridging and post-transplantation periods suggests the pos-
sibility that LVAD therapy may be the preferred initial
bridging strategy. Although the risk of dying while receiving
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IV inotropes is lower than the risk with LVAD therapy in
the first few weeks, this advantage might diminish with
longer United Network for Organ Sharing (UNOS) status 1
waiting times (5). End-organ function may remain impaired
during inotropic therapy, and patients often remain bed-
bound. However, LVAD bridging allows relatively superior
recovery of end-organ function and more significant reha-
bilitation, with the potential for better post-transplantation
outcomes (6–8).
We retrospectively reviewed the pre- and post-
transplantation outcomes of patients bridged to transplan-
tation with either LVAD or IV inotropic therapy. We
hypothesized that overall survival, including both the pre-
and post-transplantation periods, would be superior in the
LVAD group, and that fewer deaths would occur in the
LVAD group in the post-transplantation period. This
outcome would be expected to improve donor heart utili-
zation.
METHODS
We retrospectively evaluated the survival experience of adult
patients (age17 years) who were treated with IV inotropes
or an implantable LVAD as a bridge to transplantation at
the University of Michigan Medical Center from April 1,
1996 (our acquisition date for the HeartMate LVAD
[Thoratec, Inc., Pleasanton, California]) to May 10, 2001,
with follow-up through May 10, 2001. During this period,
66 patients were bridged with either a HeartMate Implant-
able Pneumatic or Vented Electric LVAD (LVAD group).
The inotrope group consisted of 38 patients who were
bridged exclusively with one or more IV inotropes admin-
istered continuously in the hospital (n  34) or at home
(n  4), with UNOS 1, 1A or 1B waiting-list status.
Patients who began therapy with an IV inotrope but later
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required LVAD therapy were considered only in the LVAD
group; the onset of bridging support for these patients was
taken as the time of LVAD implantation. Only patients
receiving an implantable LVAD were considered in the
analysis of the LVAD group.
We evaluated survival for three periods: 1) survival to
transplantation (survival from the onset of bridging support
[initiation of IV inotropes and UNOS status 1, 1A or 1B
status for the inotrope group; LVAD implantation for the
LVAD group] to heart transplantation); 2) post-
transplantation survival (survival from transplantation to the
end of follow-up); and 3) overall survival (survival from the
onset of bridging support to the end of follow-up). Actuarial
survival was calculated by the Kaplan-Meier method. For
survival to transplantation, the survival time was censored at
the time of transplantation.
Follow-up was complete for all patients. For comparative
purposes, we also examined the post-transplantation sur-
vival experiences of patients who underwent UNOS status 2
transplantation during the same period.
The study protocol was approved by the Institutional
Review Board for Human Investigation at the University of
Michigan (October 25, 2001).
Statistical analysis. Data are presented as the mean value
 SD or median value. Survival time comparisons between
groups were made using the log-rank test (SPSS version
10.1; SPSS Inc., Chicago, Illinois). The number of deaths
occurring after transplantation in the LVAD and inotrope
groups was compared using the two-tailed Fisher exact test.
A comparison of mean values was performed by using
analysis of variance and the independent sample t test with
the Bonferroni correction for multiple comparisons. Statis-
tical significance was defined at p  0.05.
RESULTS
There were no significant differences in age, gender or
etiology of heart failure between the groups (Table 1). The
cardiac index at the initiation of bridging was significantly
(p  0.05) greater in the inotrope group than in the LVAD
group (Table 1). There were no significant differences
between the groups in heart rate, mean arterial pressure,
mean pulmonary artery pressure, pulmonary capillary wedge
pressure, right atrial pressure or pulmonary vascular resis-
tance.
At the time of LVAD implantation, 15 patients (23%)
were supported with extracorporeal membrane oxygenation
(ECMO) or an extracorporeal ventricular assist device
(VAD); 20 (30%) were supported with two or more ino-
tropes, with or without a vasopressor; 12 (18%) were
supported with a single inotrope; 14 (21%) were supported
with intra-aortic balloon counterpulsation, with or without
additional inotropic support; and 5 (8%) received anti-
arrhythmic agents only, without inotropic support for severe
life-threatening ventricular arrhythmias.
In the inotrope group, 10 patients (26%) were listed as
UNOS status 1A, 14 (37%) as UNOS status 1B and 14
(37%) as UNOS status 1 (previous UNOS listing criteria).
Nineteen patients (50%) were supported with high-dose IV
inotropic therapy, defined as: 1) dopamine or dobutamine
7.5 g/kg per min; 2) milrinone 0.5 g/kg per min; 3)
multiple inotropes with dopamine or dobutamine5 g/kg
per min and milrinone0.25 g/kg per min; or 4) any dose
of an inotrope in combination with norepinephrine or
neosynephrine. Nineteen patients (50%) were supported
with low-dose IV inotropic therapy (not meeting the criteria
for high-dose inotropic therapy). Five patients in the ino-
trope group were placed on ECMO (n  2) or received an
intra-aortic balloon pump (n  3) for acute hemodynamic
deterioration or ventricular arrhythmia 24 to 48 h before
death or transplantation. These five patients did not receive
LVAD therapy, because of technical issues (post-infarct
ventricular septal defect [VSD], n  1; mechanical aortic
prosthesis and previous mediastinitis with sternal wound
closure by a rectus muscle transposition flap, n  1) or the
development of complications contraindicating transplanta-
tion immediately after the initiation of ECMO or intra-
aortic balloon pump support (n  3).
Of the 38 patients in the inotrope group, 22 (58%) were
potential candidates for LVAD therapy, if necessary, but the
attending cardiologist determined they were clinically stable
Abbreviations and Acronyms
ECMO  extracorporeal membrane oxygenation
IV  intravenous
LVAD  left ventricular assist device
UNOS  United Network for Organ Sharing
VAD  ventricular assist device
VSD  ventricular septal defect
Table 1. Patient Characteristics at Initiation of Bridging
to Transplantation
LVAD Group
(n  66)
Inotrope Group
(n  38)
Age (yrs) 49  13 49  15
Gender
Male 51 (77%) 27 (71%)
Female 15 (23%) 11 (29%)
Etiology
Ischemic 39 (59%) 17 (45%)
Nonischemic 27 (41%) 21 (55%)
Hemodynamic data
Heart rate (beats/min) 88  20 90  19
MAP (mm Hg) 73  12 76  8
RAP (mm Hg) 12  6 13  7
MPAP (mm Hg) 32  9 34  9
PCWP (mm Hg) 23  7 24  7
CI (l/min per m2) 2.0  0.6* 2.6  0.9
PVR (Wood’s unit) 2.4  1.4 2.3  1.0
*Significantly (p  0.05) different from the inotrope group. Data are presented as the
mean value  SD or number (%) of patients.
CI  cardiac index; LVAD  left ventricular assist device; MAP  mean arterial
pressure; MPAP  mean pulmonary artery pressure; PCWP  pulmonary capillary
wedge pressure; PVR pulmonary vascular resistance; RAP right arterial pressure.
1248 Aaronson et al. JACC Vol. 39, No. 8, 2002
LVAD Improves Utilization of Donor Hearts April 17, 2002:1247–54
on inotropic therapy. Sixteen patients (42%) in the inotrope
group were thought to have characteristics making them
either very high risk or ineligible for LVAD therapy, such as
a small body surface area (n  7), complex congenital heart
disease (n  5), hypertrophic cardiomyopathy (n  1),
ascending aortic aneurysm (n  1), post-infarct VSD (n 
1) and mechanical aortic prosthesis and previous mediasti-
nitis with sternal wound closure by a rectus muscle trans-
position flap (n  1). Survival to transplantation was not
significantly different (p  0.52) different between patients
in the inotrope group who were potentially eligible for
LVAD therapy and those ineligible because of high-risk
factors (Fig. 1).
Survival to transplantation. Of the 66 patients in the
LVAD group, 48 (73%) survived to transplantation, 12
(18%) died before transplantation and 6 (9%) are still on the
waiting list. Of the 38 patients in the inotrope group, 28
(74%) survived to transplantation and 10 (26%) died before
transplantation (Table 2). Actuarial survival on the waiting
list for the two groups is shown in Figure 2. For the LVAD
group, survival to transplantation was 81  5% at one and
three months (and all the way to 11.5 months), with a
median time to transplantation of 2.9 months; all pre-
transplantation deaths occurred by 19 days after LVAD
implantation (Table 2). Survival to transplantation without
LVAD therapy for the inotrope group was 78  8% at one
month and 64  11% at three months, with a median time
to transplantation of 2.9 months. Although waiting-list
survival appears to deteriorate with longer waiting times for
the inotrope group, the survival curves were not significantly
different (p  0.2).
Post-transplantation survival. Forty-eight patients in the
LVAD group and 28 patients in the inotrope group received
a heart transplant. The characteristics for these patients and
for 60 patients who received an UNOS status-2 transplant
during the same period are shown in Table 3. There were no
significant differences between patients in the LVAD group
and those in the inotrope group in terms of the recipient’s
Figure 1. Survival to transplantation of patients in the inotrope group who were potentially eligible for left ventricular assist device (LVAD) therapy and
those ineligible because of high-risk factors.
Table 2. Causes of Death Before and After Transplantation
LVAD Group (n) Inotrope Group (n)
Pre-transplantation causes of death Cerebrovascular accident (1) Cerebrovascular accident (1)
Device failure (1) Multisystem organ failure/sepsis (4)
Hemorrhage (1) Sudden death (2)
Multisystem organ failure/sepsis (5) Refractory cardiogenic shock (3)
Right-sided circulatory failure (4)
(n  12)
(n  10)
Post-transplantation causes of death Cerebrovascular accident (1) Cerebrovascular accident (1)
Rejection (acute) (1) Infection (3)
(n  2) Hemorrhage (1)
Primary allograft dysfunction (1)
Rejection (acute) (3)
(n  9)
LVAD  left ventricular assist device.
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age, the donor’s age, gender, the donor and recipient’s
weight and height, etiology of heart failure, allograft isch-
emic time or pre-transplantation length of stay. Serum
creatinine and total bilirubin were significantly (p  0.05)
lower in the LVAD group than in the inotrope group at the
time of transplantation (0.99  0.34 mg/dl vs. 1.48  0.59
mg/dl and 0.75  0.39 mg/dl vs. 0.98  0.47 mg/dl,
respectively). Fewer post-transplantation deaths occurred in
the LVAD group than in the inotrope group (2 [4%] of 48
patients in the LVAD group vs. 9 [32%] of 28 patients in
the inotrope group; p 0.045), despite a similar duration of
follow-up and pattern of censoring (Table 2). Post-
transplantation actuarial survival rates for the LVAD and
inotrope groups are shown in Figure 3. Post-transplantation
survival was significantly better for the LVAD group (98 
2% at one year and 95  4% at three and four years) than
for the inotrope group (74  9% at one year and 65  10%
at three and four years; p  0.007). Improved post-
transplantation survival with LVAD therapy resulted in a
much lower death rate in the first year, after which the
survival experiences for both groups were similar.
To investigate the hypothesis that patients in the
inotrope group who were not eligible for LVAD therapy
because of technical reasons were more ill, which would
have adversely affected post-transplantation survival in
this group, we analyzed post-transplantation survival in
the inotrope group according to whether patients were
considered as potential candidates (n  22) or not
Figure 2. Survival to transplantation: left ventricular assist device (LVAD) group versus inotrope group.
Table 3. Patient and Donor Characteristics at Heart Transplantation
LVAD Group
(n  48)
Inotrope Group
(n  28)
UNOS Status 2
Group (n  60)
Recipient age at transplantation (yrs) 46  13* 49  15 52  13
Donor age (yrs) 33  13 28  12* 37  14
Gender
Male 35 (73%) 19 (68%) 39 (65%)
Female 13 (27%) 9 (32%) 21 (35%)
Etiology
Ischemic 24 (50%) 11 (39%) 36 (60%)
Nonischemic 24 (50%) 17 (61%) 24 (40%)
Recipient weight (kg) 77  13 74  17 77  17
Donor weight (kg) 79  16 83  16 77  16
Recipient height (cm) 172  10 172  8 170  10
Donor height (cm) 172  10 177  8* 170  10
Total LOS (days) 59  57* 55  60* 23  22
Post-transplant LOS (days) 20  16 16  9 17  11
Allograft ischemic time (min) 184  38 184  44 188  41
Waiting time to transplantation (months) 4.6  5.1* 7.2  7.9 10.3  7.6
[2.9] [2.9] [9.6]
*Significantly (p  0.05) different from the UNOS status 2 group. Data are presented as the mean value  SD, number (%) of
patients or [median value].
LOS  length of stay in hospital; LVAD  left ventricular assist device; UNOS  United Network for Organ Sharing.
1250 Aaronson et al. JACC Vol. 39, No. 8, 2002
LVAD Improves Utilization of Donor Hearts April 17, 2002:1247–54
eligible (n  16) for LVAD therapy. Patients not eligible
for LVAD therapy because of technical reasons had
superior, but not significant, post-transplantation sur-
vival, as compared with patients considered as potential
candidates for LVAD therapy (Fig. 4).
Post-transplantation survival for patients who received an
UNOS status-2 transplant was 86 4%, 77 7% and 77
7% at one, three and four years, respectively. There was a
nonsignificant trend (p  0.1) toward improved survival for
patients in the LVAD group, as compared with those
patients awaiting an UNOS status-2 transplant, as shown in
Figure 5. The recipient age of patients in the LVAD group
was significantly younger than that of patients awaiting an
UNOS status-2 transplant (Table 3). The donor age of
patients awaiting an UNOS status-2 transplant was signif-
icantly older that that of the inotrope group, but was not
different from that of the LVAD group. The waiting time
to transplantation of UNOS status-2 patients was signifi-
cantly longer than that of patients who received a transplant
while on LVAD support.
Overall survival. Overall survival for the LVAD and
inotrope groups from the onset of bridging support is shown
in Figure 6. Actuarial survival was significantly better for the
LVAD group (80  5% at one year and 77  6% at three
Figure 3. Post-transplantation survival: left ventricular assist device (LVAD) group versus inotrope group.
Figure 4. Post-transplantation survival: inotrope group only (classified into patients who were potential candidates for left ventricular assist device [LVAD]
therapy and those considered not eligible because of high-risk factors).
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and four years) than for the inotrope group (56 8% at one
year and 44  9% at three and four years; p  0.03 vs.
LVAD group).
DISCUSSION
Overall survival for patients who were bridged to transplan-
tation with an implantable LVAD was superior to that of
patients who were bridged with IV inotropes. This resulted
from a nonsignificant trend toward improved survival up to
transplantation and a statistically significant improvement
in post-transplantation survival (i.e., donor heart survival)
for the LVAD group. These data demonstrate that the early
perioperative mortality associated with LVAD implantation
is offset by improved survival with longer waiting times to
transplantation and improved post-transplantation survival.
Given the critical shortage of donor organs, a substantial
benefit of LVAD bridging is the improved utilization of
donor hearts.
Frazier et al. (6) reported on the outcomes of 19 patients
bridged to heart transplantation with the pneumatic Heart-
Mate LVAD. When these patients were compared with 12
historic control subjects who met the criteria for enrollment
in their trial, but did not receive the device, survival to
transplantation was significantly improved in those receiv-
ing mechanical circulatory support. Survival to transplanta-
tion at 60 days was 100% in the device group and 20% in
Figure 5. Post-transplantation survival: left ventricular assist device (LVAD) group vs. patients transplanted as United Network for Organ Sharing status 2.
Figure 6. Overall survival from the time of bridging to follow-up: left ventricular assist device (LVAD) group versus inotrope group.
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control subjects. In a follow-up multicenter study including
75 patients who had a device implant and 33 control
subjects, 71% of those with a device survived to transplan-
tation, as compared with 36% of control subjects (7). The
one-year post-transplantation survival rate was 90% in
patients with mechanical circulatory support and 67% in
control subjects. Massad et al. (8) compared transplantation
outcomes in 53 patients receiving mechanical circulatory
support as a bridge to transplantation with the HeartMate
LVAD with 203 patients who were transplanted without
LVAD support (both UNOS status 1 and 2). Neither,
post-transplantation length of stay, operative mortality nor
one-year transplantation survival (94% for the LVAD group
and 88% for the group without mechanical support) was
significantly different between the groups. Bank et al. (9)
also assessed transplantation outcomes in 26 patients who,
while awaiting transplantation on inotropic therapy, deteri-
orated clinically, requiring consideration for LVAD ther-
apy. Twenty patients received an LVAD and six remained
on inotropic therapy. After transplantation, the incidence of
renal failure and right heart failure was significantly higher
in the group of patients remaining on inotropic therapy.
Six-month survival was not significantly different between
the groups.
More recently, Jaski et al. (10) from the Cardiac Trans-
plant Research Database Research Group reported on the
heart transplant outcomes of patients supported with
LVAD versus IV inotropic therapy. The survival of 502
patients receiving LVAD support was not significantly
different from the 2,514 patients receiving inotropic therapy
as a bridge to transplantation. Multivariate Cox regression
analysis did not identify LVAD as a significant risk factor
for mortality. The LVAD recipients had a significantly
lower rate of freedom from first infection, as compared with
the inotrope group. Freedom from rejection was not differ-
ent between the groups. The differences in the conclusions
reached in our study and those by Jaski et al. (10) may be
attributed to the inclusion of extracorporeal VADs and the
earlier period of LVAD implants (i.e., before 1996). Fur-
ther, differences in the acuity of illness (i.e., degree of
inotropic support [high-dose vs. low-dose]) between pa-
tients on IV inotropes at the time of transplantation may
have existed.
The registry of the International Society of Heart and
Lung Transplantation has identified the VAD as an inde-
pendent risk factor for post-transplantation mortality (11).
However, this registry includes both extracorporeal, para-
corporeal and implantable LVADs, as well as patients with
biventricular or univentricular support, and the data were
accumulated over an extended period. Thus, it is difficult to
extrapolate these findings to our study, which included a
more homogeneous group with only implantable LVADs
during a more recent period. The reasons for our observa-
tion that LVAD therapy improves overall survival may
reflect an improved knowledge base of selection criteria for
optimal LVAD candidates (3), as well as a willingness to
allow full recovery of end-organ function and rehabilitation
before considering transplantation. Only 4 (8.3%) of 48
patients received a heart transplant within 30 days of LVAD
implantation, and serum creatinine and total bilirubin were
significantly lower in the LVAD group than in the inotrope
group at the time of transplantation.
Observations from the present study and previous reports
support the conclusion that patients requiring prolonged
inotropic therapy have a poor survival rate while they wait
for a heart transplant. In a retrospective review of prognostic
indexes of 125 heart transplant candidates being admitted
for inotropic therapy, Gronda et al. (5) reported a one-year
survival rate of 65% for patients requiring inotropic support
as a bridge to heart transplantation. In patients who re-
quired IV pharmacologic circulatory support for more than
21 days and did not receive a suitable donor heart within
this period, 50% of patients died while waiting for a heart
transplant. These authors suggested implantation of a cir-
culatory assist device in this high-risk group awaiting heart
transplantation for longer than 21 days. These data, in
conjunction with data that support survival with LVAD
bridging to transplantation approaching 75% to 80% (8),
suggest that LVAD therapy may be the therapy of choice in
patients requiring prolonged inotropic therapy.
Study limitations. There are a number of limitations of
this study. First, this was a retrospective review, and
conclusions were based on a small, nonrandomized sample
of patients. However, a number of factors suggest that
patients in the LVAD group were more severely ill than
those in the inotrope group. Patients in the inotrope group
had a significantly higher cardiac index at the time of
bridging. Also, 50% of patients receiving inotropic therapy
had stable hemodynamic data on low-dose inotropes,
whereas nearly half of the patients treated with an LVAD
required either ECMO, an extracorporeal VAD or an
intra-aortic balloon pump at the time of LVAD bridging.
Furthermore, donor age, which is a significant determinant
of transplantation survival (11), was significantly younger
for patients transplanted in the inotrope group. Despite
these important biases in favor of inotrope therapy, post-
transplantation survival for patients in the LVAD group was
significantly better than that in the inotrope group.
Conclusions. Treatment with LVAD as a bridge to heart
transplantation appears to yield significantly improved over-
all long-term survival and, importantly, conserves donor
hearts. With longer waiting times to transplantation and
improving trends in LVAD survival, LVAD therapy, as
opposed to prolonged inotropic therapy, may be the pre-
ferred method of bridging to heart transplantation.
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